{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T04:53:40Z","timestamp":1782708820299,"version":"3.54.5"},"reference-count":21,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"unspecified","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","award":["1 U01PS005259-01-00"],"award-info":[{"award-number":["1 U01PS005259-01-00"]}],"id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,7,6]]},"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>There is high interest in long-acting injectable antiretroviral therapy (LAI-ART) among people with HIV (PWH), with many conveniences for uptake and persistence. However, both patients and clinicians have expressed important barriers to effective implementation, including concerns about frequent clinic visits and strain on clinic resources. Administration of LAI-ART by a trained layperson injector (such as family, friend or partner of the patient) can help mitigate some of these patient-identified and clinician-identified barriers. Alternative LAI-ART delivery methods have the potential to increase the PWH and layperson injector\u2019s confidence, empowerment, convenience, privacy and self-management skills and ultimately facilitate LAI-ART uptake and persistence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>INVITE-Home (innovative administration of long-acting injectables for HIV treatment enhancement at home) will support the expansion of LAI-ART in non-clinical settings by developing, implementing and evaluating a comprehensive, theory-informed training to support the administration of LAI-ART by a trained layperson injector. First, INVITE-Home will design and develop an innovative, theory-based layperson injector training to improve acceptability and uptake of LAI-ART in home-based settings, grounded in qualitative evaluation of training barriers and needs of PWH, layperson injectors and clinicians to develop the training. In Aim 2, INVITE-Home will enhance understanding of home-based LAI-ART using the training, by examining implementation and effectiveness of home-based LAI-ART injections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This study and its protocols have been approved by the University of California, San Francisco (UCSF) Institutional Review Board and the scientific staff of HIV Research Branch, Division of HIV Prevention, National Center for HIV\/AIDS, Viral Hepatitis, STD and TB Prevention, at the Centers for Disease Control and Prevention. Study staff will disseminate findings locally (eg, to partnering clinics, via the UCSF Center for AIDS Prevention Studies\u2019 Community Engagement Core), statewide (eg, the California Department of Public Health\u2019s Office of AIDS) and nationally at conferences related to HIV.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT06488846\">NCT06488846<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2024-097921","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T18:25:29Z","timestamp":1754418329000},"page":"e097921","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Innovative administration of long-acting injectables for HIV treatment enhancement at home (INVITE-HOME): implementation science study protocol"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct06488846","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7537-6350","authenticated-orcid":false,"given":"Beth","family":"Bourdeau","sequence":"first","affiliation":[{"name":"Medicine, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Rebchook","sequence":"additional","affiliation":[{"name":"Medicine, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Starley B","family":"Shade","sequence":"additional","affiliation":[{"name":"Medicine, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"O\u2019Shea","sequence":"additional","affiliation":[{"name":"CDC, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Buchacz","sequence":"additional","affiliation":[{"name":"CDC, Atlanta, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orlando","family":"Harris","sequence":"additional","affiliation":[{"name":"Department of Community Health Systems, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallory O","family":"Johnson","sequence":"additional","affiliation":[{"name":"Medicine, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Palomares","sequence":"additional","affiliation":[{"name":"Medicine, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia T","family":"Bolton","sequence":"additional","affiliation":[{"name":"Medicine, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Van Nuys","sequence":"additional","affiliation":[{"name":"Medicine, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Moore","sequence":"additional","affiliation":[{"name":"Medicine, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3793-5112","authenticated-orcid":false,"given":"Parya","family":"Saberi","sequence":"additional","affiliation":[{"name":"Medicine, University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"key":"2025123106453027000_15.8.e097921.1","unstructured":"Centers for Disease Control and Prevention . Monitoring selected national hiv prevention and care objectives by using HIV surveillance data: United States and 6 dependent areas. 2018. Available: http:\/\/www.cdc.gov\/hiv\/library\/reports\/hiv-surveillance.html [Accessed 15 Mar 2021]."},{"key":"2025123106453027000_15.8.e097921.2","unstructured":"Centers for Disease Control and Prevention . Behavioral and clinical characteristics of persons with diagnosed HIV infection\u2014medical monitoring project, United States 2020 cycle (june 2020\u2013May 2021). Available: https:\/\/www.cdc.gov\/hiv\/library\/reports\/hiv-surveillance-special-reports\/no-29\/index.html [Accessed 10 Apr 2022]."},{"key":"2025123106453027000_15.8.e097921.3","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/COH.0000000000000158","article-title":"Implementation challenges for long-acting antivirals as treatment","volume":"10","author":"Havlir","year":"2015","journal-title":"Curr Opin HIV AIDS"},{"key":"2025123106453027000_15.8.e097921.4","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2020.0126"},{"key":"2025123106453027000_15.8.e097921.5","unstructured":"FDA News Release . FDA approves first extended-release, injectable drug regimen for adults living with HIV. Available: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-extended-release-injectable-drug-regimen-adults-living-hiv [Accessed 15 Mar 2021]."},{"key":"2025123106453027000_15.8.e097921.6","unstructured":"ViiV Healthcare . Cabenuva (package insert). 2021. Available: https:\/\/gskpro.com\/content\/dam\/global\/hcpportal\/en_US\/Prescribing_Information\/Cabenuva\/pdf\/CABENUVA-PI-PIL-IFU2-IFU3.PDF"},{"key":"2025123106453027000_15.8.e097921.7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/QCO.0000000000000701","article-title":"Long-acting injectable HIV therapies: the next frontier","volume":"34","author":"Thornhill","year":"2021","journal-title":"Curr Opin Infect Dis"},{"key":"2025123106453027000_15.8.e097921.8","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1089\/apc.2018.0198","article-title":"Long-Acting Injectable Antiretroviral Treatment Acceptability and Preferences: A Qualitative Study Among US Providers, Adults Living with HIV, and Parents of Youth Living with HIV","volume":"33","author":"Simoni","year":"2019","journal-title":"AIDS Patient Care STDS"},{"key":"2025123106453027000_15.8.e097921.9","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1007\/s10461-020-02918-x","article-title":"Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 Trials","volume":"24","author":"Mantsios","year":"2020","journal-title":"AIDS Behav"},{"key":"2025123106453027000_15.8.e097921.10","doi-asserted-by":"crossref","unstructured":"Koren DE , Fedkiv V , Zhao H , et al . Perceptions of Long-Acting Injectable Antiretroviral Treatment Regimens in a United States Urban Academic Medical Center. J Int Assoc Provid AIDS Care 2020;19. doi:10.1177\/2325958220981265","DOI":"10.1177\/2325958220981265"},{"key":"2025123106453027000_15.8.e097921.11","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/QAI.0000000000002337","article-title":"Multisite Study of Women Living With HIV\u2019s Perceived Barriers to, and Interest in, Long-Acting Injectable Antiretroviral Therapy","volume":"84","author":"Philbin","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2025123106453027000_15.8.e097921.12","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1007\/s10461-019-02701-7","article-title":"A Conjoint Analysis of the Acceptability of Targeted Long-Acting Injectable Antiretroviral Therapy Among Persons Living with HIV in the U.S","volume":"24","author":"Simoni","year":"2020","journal-title":"AIDS Behav"},{"key":"2025123106453027000_15.8.e097921.13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/COH.0000000000000606","article-title":"Long-acting injectable therapy: an emerging paradigm for the treatment of HIV infection","volume":"15","author":"D\u2019Amico","year":"2020","journal-title":"Curr Opin Hiv Aids Jan"},{"key":"2025123106453027000_15.8.e097921.14","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2174\/1570162X18666200824104140","article-title":"Emerging Trends in the Long-Acting Antiretroviral Therapy: Current Status and Therapeutic Challenges","volume":"19","author":"Labh","year":"2021","journal-title":"Curr HIV Res"},{"key":"2025123106453027000_15.8.e097921.15","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/cid\/ciae016","article-title":"Virological Failure After Switch to Long-Acting Cabotegravir and Rilpivirine Injectable Therapy: An In-depth Analysis","volume":"79","author":"van Welzen","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025123106453027000_15.8.e097921.16","doi-asserted-by":"crossref","first-page":"e145","DOI":"10.1016\/S2352-3018(22)00031-5","article-title":"Equity in access to long-acting injectables in the USA","volume":"9","author":"Hojilla","year":"2022","journal-title":"Lancet HIV"},{"key":"2025123106453027000_15.8.e097921.17","doi-asserted-by":"crossref","unstructured":"Smith JD , Li DH , Rafferty MR . The Implementation Research Logic Model: a method for planning, executing, reporting, and synthesizing implementation projects. Implement Sci 2020;15. doi:10.1186\/s13012-020-01041-8","DOI":"10.1186\/s13012-020-01041-8"},{"key":"2025123106453027000_15.8.e097921.18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QMH.0000000000000157","article-title":"Measuring Organizational Capacity to Accelerate Health Care Innovation in Academic Health Centers","volume":"27","author":"Lombardi","year":"2018","journal-title":"Qual Manag Health Care"},{"key":"2025123106453027000_15.8.e097921.19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1748-5908-9-7","article-title":"Organizational readiness for implementing change: a psychometric assessment of a new measure","volume":"9","author":"Shea","year":"2014","journal-title":"Implementation Sci"},{"key":"2025123106453027000_15.8.e097921.20","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/00126334-200502010-00011","article-title":"HIV\/AIDS and Antiretroviral Treatment Knowledge, Attitudes, Beliefs, and Practices in HIV-Infected Adults in Soweto, South Africa","volume":"38","author":"Nachega","year":"2005","journal-title":"JAIDS Journal of Acquired Immune Deficiency Syndromes"},{"key":"2025123106453027000_15.8.e097921.21","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13012-017-0635-3","article-title":"Psychometric assessment of three newly developed implementation outcome measures","volume":"12","author":"Weiner","year":"2017","journal-title":"Implementation Sci"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2024-097921","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T14:46:05Z","timestamp":1767192365000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2024-097921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":21,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,8,5]]},"published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1136\/bmjopen-2024-097921"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2024-097921","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]}}}